Skip to main
MDLN

Medline Inc (MDLN) Stock Forecast & Price Target

Medline Inc (MDLN) Analyst Ratings

Based on 23 analyst ratings
Buy
Strong Buy 35%
Buy 52%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Medline experienced a significant increase in sales revenue, rising 11.47% year-over-year from $25.51 billion to $28.43 billion for the 12 months ending December 2025. The company's Return on Capital improved from 7.22% to 7.44%, indicating enhanced financial efficiency and profitability, while it also secured $2.4 billion in new customer signings, demonstrating robust demand for its Medline-branded products and supply chain solutions. With the Medline Brand now contributing to nearly half of the company's revenue and strong growth prospects forecasted to reach $31.12 billion, Medline is well-positioned to capitalize on its extensive manufacturing capabilities and established vendor relationships in the healthcare sector.

Bears say

Medline's economic profit showcased a stark decline of 220.79% year-over-year, shifting from a profit of $345.1 million pre-IPO to a significant loss of $416.9 million post-IPO, reflecting negative trends in equity cost measurements. Additionally, Net Operating Profit After Tax (NOPAT) fell by 12.66% year-over-year, decreasing from $2.45 billion to $2.14 billion, along with a 4.48% decline in Economic Operating Cash Flow (EBITDAR) from $3.71 billion to $3.54 billion, highlighting ongoing profitability challenges. The company faces pressure from elevated inflation, hiring challenges, low-margin healthcare operations, competitive market dynamics, and reliance on sustaining Prime Vendor agreements, all of which could adversely affect revenue growth and operational stability.

Medline Inc (MDLN) has been analyzed by 23 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 52% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Medline Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Medline Inc (MDLN) Forecast

Analysts have given Medline Inc (MDLN) a Buy based on their latest research and market trends.

According to 23 analysts, Medline Inc (MDLN) has a Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $50.48, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $50.48, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Medline Inc (MDLN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.